AstraZeneca shares drop 6% after company announces 'routine' safety pause in vaccine trial

Nigeria News News

AstraZeneca shares drop 6% after company announces 'routine' safety pause in vaccine trial
Nigeria Latest News,Nigeria Headlines
  • 📰 CNBC
  • ⏱ Reading Time:
  • 9 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 7%
  • Publisher: 72%

Dado Ruvic | Reutersshares fell more than 6% in after-hours trading Tuesday after the company said its late-stage trial for a potential coronavirus vaccine had been put on hold due to safety concerns.

"This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials, In large trials illnesses will happen by chance but must be independently reviewed to check this carefully," the company said in a statement to CNBC.

It said it was trying to expedite the review to "minimize any potential impact on the trial timeline."This is a developing story. Please check back for updates.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

CNBC /  🏆 12. in US

Nigeria Latest News, Nigeria Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Drug company CEOs issue vaccine safety pledgeDrug company CEOs issue vaccine safety pledgeThe chief executives of nine drug companies pledged Tuesday not to seek regulatory approval before the safety and efficacy of their experimental coronavirus vaccines have been established in Phase 3 clinical trials, according to reporting.
Read more »

Australia's secures access to AstraZeneca COVID-19 vaccine within monthsAustralia's secures access to AstraZeneca COVID-19 vaccine within monthsAustralia on Monday said it will receive the first batches of a potential COVID-19 vaccine in January 2021, as the country's virus hotspot said the number of new daily infections has fallen to a 10-week low.
Read more »

Pfizer and BioNTech approved to start phase 2/3 trial of Covid-19 vaccinePfizer and BioNTech approved to start phase 2/3 trial of Covid-19 vaccineA German regulatory authority has approved a phase 2/3 clinical trial in Germany of a Covid-19 vaccine candidate being developed by US pharmaceutical company Pfizer and German biotechnology company BioNTech
Read more »

9 vaccine makers sign safety pledge in race for Covid-19 vaccine9 vaccine makers sign safety pledge in race for Covid-19 vaccineNine biopharmaceutical companies sign a joint pledge to uphold 'high ethical standards' around developing Covid-19 vaccines, suggesting they won't seek premature government approval
Read more »

Pharma CEOs Counter Trump By Promising Safety Over Shortcuts In Coronavirus Vaccine DevelopmentPharma CEOs Counter Trump By Promising Safety Over Shortcuts In Coronavirus Vaccine DevelopmentA “historic pledge” is intended to counter President Trump’s insistence that a vaccine could be ready by Election Day.
Read more »

Australia expects to receive AstraZeneca's COVID-19 vaccine within monthsAustralia expects to receive AstraZeneca's COVID-19 vaccine within monthsAustralia expects to receive its first batches of a potential COVID-19 vaccine in January, Prime Minister Scott Morrison said on Monday, as the number of new daily infections in the country's virus hotspot fell to a 10-week low.
Read more »



Render Time: 2025-08-27 13:16:48